Emerging therapies in Ewing sarcoma

Cancer research · Ewing sarcoma

The article outlines innovative strategies for evaluating novel agents in relapsed Ewing sarcoma, emphasizing second‑strike therapies, adaptive trial designs, and systematic collection of correlative samples to accelerate development of effective treatments.

Purpose of review: There is an unmet need to improve outcomes for patients for Ewing sarcoma, a rare, aggressive sarcoma with a peak incidence in adolescents and young adults (AYA). Current therapy at diagnosis involves multi‑agent chemotherapy and local therapy, but despite intensification of treatment, those with metastases at diagnosis and recurrent disease have poor outcomes. Recent findings: Improved understanding of Ewing sarcoma biology has identified novel targets with promising activity, including tyrosine‑kinase inhibitors that are now undergoing evaluation as combination and maintenance therapy. Other emerging therapies target the EWSR1::FLI1 fusion oncoprotein and act on DNA‑damage, cell‑cycle and apoptotic pathways. Immunotherapeutic approaches, particularly CAR‑T‑cell therapy directed at GD2, also hold promise. Summary: Close international collaboration between clinicians and biologists will allow prioritising promising emerging therapies and developing biomarkers to facilitate their incorporation into standard care and accelerate translation into benefit for Ewing sarcoma patients.

Relapsed Ewing sarcoma has a persistently low survival rate despite intensive standard therapy; novel therapeutic approaches and improved trial designs are urgently needed to enhance outcomes in this pediatric population.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals